Exagen (XGN) said Thursday that it priced its previously announced underwritten public offering of 3.35 million common shares at $5.25 apiece for expected gross proceeds of about $17.6 million.
The company said it granted the underwriters a 30-day option to purchase up to 502,500 additional shares at the same offering price.
Exagen expects to close the offering on Friday.
Shares of Exagen were down 8.4% in recent Thursday trading.
Price: 6.26, Change: -0.57, Percent Change: -8.35
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.